title: Human immature thymocytes as target cells of the leukemogenic activity of human T-cell leukemia virus type I.
abstract: The risk of developing adult T-cell leukemia (ATL) associated with neonatal infection by human T-cell leukemia virus type I (HTLV-I) suggests that early events triggered by HTLV-I might be of crucial importance in initiating the multistep lymphoproliferative process leading several decades later to the development of leukemic disease. Thus, infection of thymocytes early in life might be directly correlated with the development of ATL. In the present study, we show that in vitro infection of mature (CD2+CD3+) or immature (CD2+CD3-) thymocytes resulted in the exogenous interleukin (IL)-2-dependent proliferation of HTLV-I-positive thymocytes, most of them displaying a CD2+CD3-CD4+ phenotype and expressing the CD25 molecule, the alpha chain of the IL-2 receptor. Furthermore, the CD80 and CD54 antigens, normally expressed by thymic stromal cells, were detected on these transformed thymocytes, indicating that HTLV-I infection may disturb the cooperation between thymocytes and their thymic environment. These HTLV-I-positive thymocytes were producing significant amounts of IL-6, which was found to be implicated in their proliferation and in the expression of CD25, as demonstrated by blocking experiments using a monoclonal antibody to IL-6. The present study suggests that immature thymocytes may provide an environment favorable to the unfolding of events leading to leukemia.
authors.affiliation: Centre National de la Recherche Scientifique/Université Claude Bernard, Lyon, France.
authors.forename: V
authors.initials: V
authors.lastname: Maguer-Satta
authors.forename: L
authors.initials: L
authors.lastname: Gazzolo
authors.forename: M D
authors.initials: MD
authors.lastname: Dodon
mesh_terms: D002478:Cells, Cultured; D005434:Flow Cytometry; D015490:HTLV-I Infections / Q000276:immunology* / Q000473:pathology; D015368:Human T-lymphotropic virus 1 / Q000472:pathogenicity*; D006801:Humans; D016130:Immunophenotyping; D066298:In Vitro Techniques; D007223:Infant; D007376:Interleukin-2 / Q000494:pharmacology; D015850:Interleukin-6 / Q000494:pharmacology; D008213:Lymphocyte Activation / Q000187:drug effects; D015375:Receptors, Interleukin-2 / Q000502:physiology; D013950:Thymus Gland / Q000166:cytology* / Q000276:immunology / Q000382:microbiology*
chemical_list: D007376:Interleukin-2; D015850:Interleukin-6; D015375:Receptors, Interleukin-2